Zacks: Brokerages Anticipate AMAG Pharmaceuticals, Inc. (AMAG) Will Post Quarterly Sales of $167.23 Million
Wall Street analysts expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report $167.23 million in sales for the current quarter, Zacks reports. Five analysts have provided estimates for AMAG Pharmaceuticals’ earnings. The lowest sales estimate is $161.86 million and the highest is $172.58 million. AMAG Pharmaceuticals reported sales of $143.78 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 16.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 2nd.
According to Zacks, analysts expect that AMAG Pharmaceuticals will report full year sales of $167.23 million for the current financial year, with estimates ranging from $638.99 million to $661.00 million. For the next year, analysts anticipate that the business will post sales of $546.78 million per share, with estimates ranging from $481.01 million to $584.07 million. Zacks’ sales calculations are an average based on a survey of analysts that follow AMAG Pharmaceuticals.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The firm had revenue of $158.39 million during the quarter, compared to analyst estimates of $158.83 million. During the same period last year, the company earned $1.45 earnings per share. The business’s revenue for the quarter was up 24.3% on a year-over-year basis.
Several brokerages recently weighed in on AMAG. Morgan Stanley began coverage on shares of AMAG Pharmaceuticals in a report on Friday, September 8th. They issued an “overweight” rating and a $26.00 target price for the company. Deutsche Bank AG reaffirmed a “hold” rating and issued a $24.00 target price on shares of AMAG Pharmaceuticals in a report on Thursday, August 31st. BidaskClub downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Cowen and Company reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a report on Thursday, August 10th. Finally, Zacks Investment Research downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 26th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and three have issued a buy rating to the stock. AMAG Pharmaceuticals currently has an average rating of “Hold” and an average price target of $27.92.
In related news, SVP Julie Krop sold 4,938 shares of the stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $20.00, for a total value of $98,760.00. Following the sale, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at approximately $566,720. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.80% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the stock. Hikari Power Ltd raised its position in AMAG Pharmaceuticals by 75.0% in the 2nd quarter. Hikari Power Ltd now owns 70,000 shares of the specialty pharmaceutical company’s stock worth $1,288,000 after purchasing an additional 30,000 shares during the period. ClariVest Asset Management LLC raised its position in AMAG Pharmaceuticals by 23.9% in the 1st quarter. ClariVest Asset Management LLC now owns 36,800 shares of the specialty pharmaceutical company’s stock worth $830,000 after purchasing an additional 7,100 shares during the period. Vanguard Group Inc. raised its position in AMAG Pharmaceuticals by 6.1% in the 1st quarter. Vanguard Group Inc. now owns 3,085,348 shares of the specialty pharmaceutical company’s stock worth $69,576,000 after purchasing an additional 176,832 shares during the period. Legal & General Group Plc raised its position in AMAG Pharmaceuticals by 1.3% in the 1st quarter. Legal & General Group Plc now owns 61,371 shares of the specialty pharmaceutical company’s stock worth $1,384,000 after purchasing an additional 770 shares during the period. Finally, Sei Investments Co. raised its position in AMAG Pharmaceuticals by 0.7% in the 1st quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after purchasing an additional 54 shares during the period.
AMAG Pharmaceuticals (NASDAQ:AMAG) traded down 3.91% during midday trading on Friday, reaching $19.65. The company had a trading volume of 1,874,354 shares. AMAG Pharmaceuticals has a 52 week low of $16.00 and a 52 week high of $36.83. The company’s market capitalization is $693.41 million. The firm has a 50-day moving average price of $18.20 and a 200-day moving average price of $19.90.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.